Taiho Pharmaceutical Co., Ltd.
68
4
10
47
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
10.3%
7 terminated/withdrawn out of 68 trials
87.0%
+0.5% vs industry average
31%
21 trials in Phase 3/4
28%
13 of 47 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (68)
TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer
Role: collaborator
Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas
Role: collaborator
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
Role: collaborator
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Role: collaborator
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
Role: lead
A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)
Role: lead
A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome
Role: lead
A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy（REACH-DMD）
Role: lead
A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC
Role: collaborator
TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma
Role: collaborator
Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.
Role: lead
A Phase I Study of TAS-102 in Solid Tumors
Role: lead
Exploratory Trial of TAS-303 in Female Patients With Stress Urinary Incontinence
Role: lead
AB122 Platform Study
Role: lead
A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
Role: collaborator
A Study of TAS3731 in Healthy Adults
Role: lead
A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria
Role: lead
TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma
Role: collaborator
A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects
Role: lead
Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs
Role: collaborator